Sunday November 22 2009 | Biotechnology feed | All feeds
|
|
|
CytRx
Download detailed PDF Members: CytRx Corporation (NASDAQ: CYTR), located in Los Angeles, California, is a biopharmaceutical company engaged in the development of high-value therapeutics utilizing its core technologies in small molecule drugs, RNAi drug discovery and DNA vaccines. CytRx's small molecule drug candidates provide cellular protection by activating "molecular chaperone" proteins that can repair or degrade proteins that are believed to cause many diseases. "Molecular chaperones" represent a therapeutic development platform from which CytRx may derive several drugs that address large markets and unmet medical needs. CytRx initiated a Phase II clinical trial with arimoclomol in ALS in September 2005. The initial Phase II trial included 84 patients treated at 10 clinical sites in the United States with initial results expected in 4Q '06. The FDA has granted Fast Track and Orphan Drug designation for arimoclomol in ALS. CytRx is a world leader in developing products based on advanced RNAi technology primarily for the human health care market. RNAi has been shown to effectively silence a targeted disease-causing gene within a living cell. CytRx has a broad based strategic alliance with the University of Massachusetts Medical School (UMMS) which has given the company unparalleled access to RNAi technology and serves as a broad platform for a myriad of drug discovery applications including obesity, type 2 diabetes, ALS (Lou Gehrig's disease), and CMV (cytomegalovirus). Additionally, CytRx has a sponsored research program with Massachusetts General Hospital, Harvard's teaching hospital, to develop therapies to treat ALS using RNAi. CytRx has also licensed from the UMMS the exclusive worldwide commercial rights to a novel DNA-based HIV vaccine technology. The HIV vaccine is based on a unique cocktail of human HIV-1 primary isolates from several genetic subtypes of HIV. Phase I clinical results announced in July 2006 indicate that the DNA + protein boost HIV vaccine, based on 5 known primary human HIV strains, was well tolerated and produced potent antibody responses with neutralizing activity against multiple HIV viral strains. This clinical program, was funded by a $16 million NIAID grant, was being conducted by CytRx, University of Massachusetts Medical School (UMMS) and Advanced BioScience Laboratories (ABL).
This page has been viewed 615 times since April 2007, the link to the organisation's website has been followed 98 times Recent Search Terms used to find this page: Bioorg Med Chem Lett. 2009 June 1 19(11) 3128-35 | 3030 Bunker Hill St building | cytrx san diego | cytrx san diego | CytRx email | cytRx Corporation CA 90049 mail | cytrx san diego | cytrx san diego | protein phosphatase 5 | cytrx bunker hill | . Search for more companies in Los Angeles Search for more companies in California This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for CytRx | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Nothing in this website should be used in
place of personal medical advice from your own qualified medical
practitioner. |
All rights reserved. All other trademarks recognized. |
|
